Barriers to HCV treatment in the era of triple therapy: A prospective multi-centred study in clinical practice

Liver International

Volumn 35, Issue 2, 2015, Pages 401-408

  Crespo, Javier ^a   Cabezas, Joaquín ^a   Sacristán, Begoña ^b   Olcoz, José L ^c   Pérez, Ramón ^d   De la Vega, Juan ^e   García, Rosa ^f   García Pajares, Félix ^g   Sáez Royuela, Federico ^h   González, José M ⁱ   Jiménez, Felipe ^j   Rodríguez, Santiago ^k   Cuadrado, Antonio ^l   López Arias, María J ^m   García, Isidro ⁿ   Milla, Ana ^o   García Riesco, Emilia ^p   Muñoz, María ^b   Sánchez Antolín, Gloria ^g   Jorquera, Francisco ^c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Department of Digestive Diseases   (Spain)

^c HOSPITAL DE LEÓN   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL SAN AGUSTÍN   (Spain)

^f HOSPITAL DE CABUEÑES   (Spain)

^g HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k Hospital Provincial de Zamora   (Spain)

^l HOSPITAL DE LAREDO   (Spain)

^m Hospital Comarcal Sierrallana   (Spain)

ⁿ HOSPITAL RÍO CARRIÓN   (Spain)

^o HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^p HOSPITAL VALLE DEL NALÓN   (Spain)

more..

Author keywords

Direct acting antiviral; Hepatitis C virus; Limitations; Treatment

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; EDUCATIONAL STATUS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STRUCTURED QUESTIONNAIRE; TREATMENT CONTRAINDICATION; TREATMENT REFUSAL; VIRUS LOAD; AGE; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPACIVIRUS; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PATIENT SELECTION; SEX DIFFERENCE; SPAIN; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; DRUG THERAPY, COMBINATION; EDUCATIONAL STATUS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROSPECTIVE STUDIES; SEX FACTORS; SPAIN; STATISTICS, NONPARAMETRIC; TREATMENT REFUSAL;

EID: 84921568873     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12536     Document Type: Article

References (31)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe. Canada and Israel. Liver Int 2011; 31(Suppl 2): 30-60.
3. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
4. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012; 19: 829-35.
5. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-9.
6. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57: 1325-32.
7. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
8. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
9. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-36.
10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
11. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
12. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
14. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19(Suppl 2): 1-26.
15. Crespo G, Lens S. Uso de boceprevir y telaprevir en pacientes con VHC (aspectos prácticos). Gastroenterol Hepatol 2012; 35: 337-43.
16. Esteban R, Buti M. Triple therapy with boceprevir or telaprevir for treatment naive HCV patients. Best Pract Res Clin Gastroenterol 2012; 26: 445-53.
17. Cunningham M, Foster GR. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012; 5: 139-51.
18. Garnock-Jones KP. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs 2012; 72: 2431-56.
19. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
20. Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12: 81-5.
21. Shehab TM, Orrego M, Chunduri R, et al. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98: 639-44.
22. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-92.
23. Couzigou P. Virus C cure as a motivation for strong lifestyle change? Clin Gastroenterol Hepatol 2012; 10: 326.
24. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.
25. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
26. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669-89.
27. AEMPS Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis crónica C (VHC) en pacientes monoinfectados. 2012. http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-VHC-monoinfectados_28-02-12.pdf. Accessed:12 April 2013.
28. Chen EY, Sclair SN, Czul F, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol 2013; 11: 1014-20 e2.
29. Deuffic-Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143: 974-85.
30. Ward JW, Rein DB, Smith BD. Data to guide the 'test and treat era' of hepatitis C. Gastroenterology 2012; 143: 887-9.
31. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.